Baxter International Inc. (BAX) stock fell 19.4% to $22.66 following the company’s announcement of its second-quarter adjusted earnings per share (EPS) of 59 cents, which matched expectations but was perceived negatively by investors, contributing to a significant drop near its 52-week low.

Baxter International Inc

Baxter International’s (BAX) stock plummeted by 22.42% following disappointing financial results and concerns raised during its earnings call, leading investors to reassess its growth prospects.

Baxter International’s (BAX) stock plummeted by 22

Baxter International (BAX) stock experienced a significant decline of -22.42%, primarily due to negative market sentiment following announcements of a 25% tariff on Indian imports and penalties for Russian oil purchases, which have raised concerns about the company's competitiveness and potential impacts on earnings.

Baxter International (BAX) stock experienced a significant decline of -22

Baxter International (BAX) stock fell by 22.42% due to the company reporting earnings below estimates and significantly lowering its guidance, primarily impacted by damage to a key manufacturing plant caused by Hurricane Helene.

Baxter International (BAX) stock fell by 22

Baxter International (BAX) stock fell by 2.4% recently, likely due to broader market trends or investor sentiment affecting the healthcare sector, although the article does not specify the exact reasons for its decline.

Baxter International (BAX) stock fell by 2

Baxter International (BAX) stock rose by 0.74% recently ahead of its anticipated Q2 2025 earnings report, where analysts expect it to surpass previous earnings estimates, bolstered by its recent performance that showcased better-than-expected earnings and revenue growth, as well as a forthcoming dividend announcement.

Baxter International (BAX) stock rose by 0

Baxter International's stock (BAX) fell by 0.43% after Morgan Stanley reduced its target price from $28.00 to $27.00, reflecting a negative sentiment with an underweight rating on the stock, amidst a backdrop of varying analysts' ratings and target adjustments.

Baxter International's stock (BAX) fell by 0

Baxter International Inc. (BAX) stock declined by 0.59% following a 12.9% decrease in the stake held by Greenleaf Trust and multiple recent downgrades from research analysts, which negatively impacted investor sentiment and price targets.

Baxter International's (BAX) stock fell by 3.37% after Evercore ISI lowered its target price for the stock from $44.00 to $42.00, amid various other negative analyst ratings and price target reductions from firms like Wells Fargo and Morgan Stanley.

Baxter International's (BAX) stock fell by 3

Baxter International Inc. (NYSE:BAX) stock fell by 0.37% as analysts have downgraded their price targets for the company, with notable cuts from Evercore ISI, Morgan Stanley, and Citigroup, leading to a general consensus rating of "Hold" amid concerns about its market performance and recent analyst expectations.

Baxter International's stock (BAX) fell by 2.77%, possibly due to the announcement of a new CEO, Andrew Hider, which may have raised concerns among investors about the company's future leadership direction and strategy.

Baxter International's stock (BAX) fell by 2

Baxter International Inc. (NYSE:BAX) stock declined by 0.32% due to mixed analyst ratings and adjustment of price targets following its latest earnings report, despite a substantial increase in institutional holdings.

Baxter International Inc. (BAX) stock decreased by 0.36%, possibly due to recent downgrades in target prices by several equity research analysts and concerns surrounding its earnings and financial ratios compared to market expectations.

Baxter International's stock (NYSE:BAX) was down 0.0%, despite upgrades and positive ratings from several analysts because of mixed sentiment in the market and reduced price targets from some firms like Morgan Stanley and Wells Fargo.

Baxter International's stock (NYSE:BAX) was down 0

Baxter International (BAX) stock remained unchanged at 0.0% last night, following a significant 40.7% reduction in shares by Praxis Investment Management Inc. during the first quarter, which may indicate a lack of confidence among institutional investors about the company's future performance.

Baxter International (BAX) stock remained unchanged at 0

Baxter International (BAX) stock fell by 2.92% last night due to investor concerns over the uncertainty surrounding the company's new CEO and its future sales strategy following the acquisition of Vantive, which could impact market growth rates.

Baxter International (BAX) stock rose by 1.95% following significant increases in investment stakes by NBC Securities Inc. and other institutional investors, reflecting positive sentiment and confidence in the company's recent earnings performance, which beat analysts’ expectations.

Baxter International (BAX) stock rose by 1

Baxter International Inc. (BAX) stock declined by 0.5% due to lowered Q3 2025 earnings per share estimates from Zacks Research, which revised its forecast down from $0.66 to $0.63, contributing to negative market sentiment.

Baxter International (NYSE:BAX) stock rose by 2.64% despite Morgan Stanley's downgrade of its target price from $30.00 to $28.00 and an "underweight" rating, as the company reported better-than-expected quarterly earnings that beat analyst estimates.

Baxter International (NYSE:BAX) stock rose by 2

Baxter International (BAX) stock fell by 0.91% due to broader concerns about the U.S. economy, including rising inflation, fears of a recession, and the impact of tariffs and trade wars on revenue and profitability across industries, contributing to a negative market sentiment.

Baxter International (BAX) stock fell by 0

Baxter International Inc. (NYSE:BAX) experienced a decline of 1.6% despite reporting strong first-quarter 2025 earnings and sales, likely due to broader market reactions or investor profit-taking after exceeding earnings expectations.

Baxter International (BAX) stock rose by 0.61% as investors look forward to the company's upcoming Q1 2025 earnings report, which is expected to meet or exceed analysts' positive forecasts for earnings and revenue.

Baxter International (BAX) stock dipped by 0.62%, primarily due to market comparisons revealing that PolyPid is perceived more favorably by analysts, possessing stronger ratings and a higher potential upside.

Baxter International (BAX) stock dipped by 0

Baxter International (BAX) stock rose by 3.85% likely due to positive market reactions surrounding Ligand Pharmaceuticals' merger with Channel Therapeutics, which aims to commercialize the innovative FDA-approved drug ZELSUVMI for treating molluscum contagiosum, a move seen as enhancing the company's growth potential and revenue opportunities.

Baxter International (BAX) stock rose by 3

Baxter International's stock (BAX) saw a 1.94% increase due to the company's effective balance of short-term accountability and long-term strategic vision amidst ongoing market uncertainties, showcasing its commitment to sustainable growth even in turbulent times.

Baxter International's stock (BAX) saw a 1

Baxter International's (BAX) stock rose by 9.94% due to a combination of successful strategic change initiatives aimed at fostering innovation and addressing operational challenges within the organization, which were highlighted during a recent analysis of their performance improvements.

Baxter International's (BAX) stock rose by 9

Baxter International Inc. (NYSE:BAX) experienced a decrease of 1.09% in its stock price, attributed to factors such as analysts adjusting their price targets, short interest decreasing, and a generally stable market performance amid mixed valuation ratings from analysts.

Baxter International Inc. (BAX) stock experienced a decline of 0.61% as it is evaluated among other undervalued healthcare stocks suggested by analysts, though the article does not provide specific reasons for the stock's drop.

Baxter International Inc. (NYSE:BAX) stock fell by 0.61%, as the company received mixed ratings from analysts, with one sell rating, four holds, and five buys, reflecting market uncertainty and varying price targets from different brokerages.

Baxter International's stock (BAX) fell by 0.98% following a downgrade in their Q1 2025 earnings estimates by Zacks Research, which reduced the expected earnings per share from $0.50 to $0.49, indicating weaker financial performance than previously anticipated.

Baxter International (BAX) stock experienced a decline of -4.02% after analysts from Stifel Nicolaus and JPMorgan Chase & Co. lowered their price targets, reflecting concerns about the company's future performance despite a recent earnings beat.

Baxter International (BAX) stock experienced a decline of -4

Baxter International (BAX) stock experienced a slight decline of 0.03%, and the drop could be attributed to fluctuating analyst ratings and target price adjustments, as well as overall market sentiments despite a positive earnings report in February.

Baxter International (BAX) stock experienced a slight decline of 0

Baxter International (BAX) stock rose by 0.8% amidst Walgreens announcing its $10 billion sale to private equity firm Sycamore Partners, which suggests potential market confidence and interest in healthcare stocks that could benefit from this development.

Baxter International (BAX) stock fell by 0.2% amid a consensus "Hold" rating from analysts, with recent price target reductions by firms like JPMorgan and Stifel Nicolaus suggesting concerns about the company's future performance.

Baxter International (BAX) stock rose by 2.45% after Argus upgraded its rating from hold to buy, reflecting positive sentiment and new investment recommendations from various financial analysts.

Headline	Summary	Source
Baxter International Inc	Baxter International Inc. (BAX) stock fell 19.4% to $22.66 following the company’s announcement of its second-quarter adjusted earnings per share (EPS) of 59 cents, which matched expectations but was perceived negatively by investors, contributing to a significant drop near its 52-week low.	BizToc
Baxter International’s (BAX) stock plummeted by 22	Baxter International’s (BAX) stock plummeted by 22.42% following disappointing financial results and concerns raised during its earnings call, leading investors to reassess its growth prospects.	Globenewswire
Baxter International (BAX) stock experienced a significant decline of -22	Baxter International (BAX) stock experienced a significant decline of -22.42%, primarily due to negative market sentiment following announcements of a 25% tariff on Indian imports and penalties for Russian oil purchases, which have raised concerns about the company's competitiveness and potential impacts on earnings.	Thehindubusinessline
Baxter International (BAX) stock fell by 22	Baxter International (BAX) stock fell by 22.42% due to the company reporting earnings below estimates and significantly lowering its guidance, primarily impacted by damage to a key manufacturing plant caused by Hurricane Helene.	Investopedia

BAX

Latest News & Analysis